Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07589855

Somatosensory Stimulation for Unilateral Neglect Post Stroke (SSUN)

Somatosensory Stimulation for Unilateral Neglect Post Stroke (SSUN) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07589855.

📅 15 May 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07589855
Sponsor
Keele University
Start
2025-10-20
ClinicaliQ Trial Snapshot
  • Somatosensory Stimulation for Unilateral Neglect Post Stroke (SSUN) — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07589855.
  • Sponsor: Keele University.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The Intervention, called Mobilization and tactile Stimulation (MTS for short) is a hands-on physical therapy technique that can be used to treat the arm and hand after a stroke. It includes joint movements, massage, and sensory input like touch and compression. MTS is part of routine therapy for stroke patients when people cannot move or feel their arm normally. It may help with problems like neglect, which is when people are not aware of one side of their body after their stroke. The effectiveness of MTS to help people with…

Eligibility Snapshot
  • : * Adult (≥18 years of age) who is an Adult stroke survivors (≥18 years of age) with a clinical diagnosis of UN, in the subacute-chronic phase of stroke (≥20 weeks post stroke) * Ability to consent to participate in the study, assessed by their understanding of the study when it is explained to them. * Sufficient cognitive and physical ability to allow inclusion in this study, assessed by the ability to follow a simple one-stage command with the non-paretic limb. * Able and willing to receive and engage with regular therapy (MTS) (e.g. at home).

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation
Cardiology / Cardiovascular · MHRA · 24 Oct 2024
A safety review has been conducted by the MHRA following a Yellow Card report concerning a patient who was taking bromocriptine. The…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Clinical Brief
Man fears stroke or heart attack due to aspirin shortage
Cardiology / Cardiovascular · BBC Health · 30 Mar 2026
David Slater, 72, says ministers need to step up and sort out issues with the medication. This update is most useful for…
View brief →
Guideline
Stroke and TIA: Diagnosis and Initial Management (NICE NG128)
Cardiology / Cardiovascular · 27 Mar 2026
Use FAST recognition (Face, Arms, Speech, Time) in primary care to identify suspected stroke and arrange immediate hospital admission as a medical…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →